Overview
Investors searching INJ vs UB usually want a clear market-cap and momentum snapshot. Injective prints $5.00 (+1.77%) while UB is at $1,867.53 (+1.00%), with volume edge currently on UB.
Quick winners
Full comparison
| Metric | INJ | UB |
|---|---|---|
| Price | $5.00 | $1,867.53 |
| Market Cap | $490.41M | $415.92M |
| FDV | — | — |
| Volume 24h | $2.50M | $26.68M |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 99.00 | 106.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.97% | +3.64% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | INJ | UB |
|---|---|---|
| 1H | — | — |
| 24H | +1.77% | +1.00% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | INJ | UB |
|---|---|---|
| RSI | 49.29 | 49.02 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.29 | 67.35 |
| ADX | 12.19 | 21.33 |
| Support | 4.91 | 1,827.82 |
| Resistance | 5.07 | 1,960.30 |
| Trend | neutral | bearish |
| Momentum | — | 65.00 |
| Signal | neutral | neutral |
Automatic technical analysis
Automated technical notes for this pair highlight neutral conditions on INJ and bearish on UB. Volatility differences can amplify short-term gaps.
Fundamentals
| Metric | INJ | UB |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | — |
| Github activity | 118.00 | — |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Injective
UB
Pros and cons
Pros of Injective
- Composite PEPS readings for Injective can surface clearer module agreement during trend phases.
- Injective typically benefits from deeper liquidity and broader market recognition inside the Top 300 set.
- Higher ranking for Injective can translate into tighter spreads on major venues.
Cons of Injective
- Large-cap status for Injective can mean slower percentage upside versus high-beta alternatives.
- Indicator stacks on Injective may stay stretched longer than expected in strong trends.
- When dominance narratives fade, Injective can lag hotter rotation names.
Pros of UB
- Narrative optionality around UB can reprice quickly when catalysts appear.
- Diversifying versus Injective with UB can change portfolio factor exposure.
- UB can offer higher relative beta when market attention rotates toward its niche.
- Active volume bursts on UB sometimes precede sharper tactical moves.
Cons of UB
- Trend failures on UB often travel faster than on more established assets.
- Relative underperformance versus Injective can persist through entire market regimes.
- Weaker market-cap standing may leave UB more exposed to liquidity droughts.
Which looks stronger right now?
Across winners above, no single coin dominates every column. Prefer scenarios: trend continuation favors the side with aligned momentum; mean-reversion favors the side stretched on RSI.
AI summary
For readers asking which is “better”, the honest answer is conditional. Injective and UB solve overlapping but not identical market jobs. On-chain and developer fields, when available, add slower-moving context beneath the tape. Missing fundamentals should be treated as unknown, not as zeros. If your thesis is long-term adoption, weight fundamentals and liquidity; if tactical, weight trend/momentum — and always define invalidation.
FAQ
Which is better, Injective or UB?
“Better” depends on horizon and risk. Injective leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, INJ or UB?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Injective and UB.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. UB currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.